exjade
novartis europharm limited - deferasiroks - beta-thalassemia; iron overload - vsi drugi terapevtski izdelki - exjade je indicirano za zdravljenje kronične prenasičenosti z železom zaradi pogostih transfuzijah krvi (≥ 7 ml/kg/mesec pakiranih rdečih krvničk) pri bolnikih z beta thalassaemia večjih starih šest let in starejši. exjade je tudi navedeno, za zdravljenje kronične železa preobremenitve zaradi transfuzije krvi, če deferoxamine zdravljenje je kontraindicirano ali neustrezni v naslednjih bolnik skupine:pri bolnikih z beta talasemija major preobremenitve z železom zaradi pogoste transfuzije krvi (≥ 7 ml/kg/mesec pakirani rdečih krvnih celic), starih od dve do pet let;pri bolnikih z beta talasemija major preobremenitve z železom zaradi redke transfuzije krvi (< 7 ml/kg/mesec pakirani rdečih krvnih celic), starih od dveh let in starejše;pri bolnikih z drugimi anaemias v starosti dveh let in starejši. exjade je tudi navedeno, za zdravljenje kronične železa preobremenitve, ki zahtevajo chelation therapy, ko deferoxamine zdravljenje je kontraindicirano ali neustrezni pri bolnikih z ne-transfuzijo odvisna talasemija sindromov, starih 10 let in več.
orphacol
theravia - holinska kislina - digestive system diseases; metabolism, inborn errors - Žolčnih kislin in derivati - orphacol je indicirano za zdravljenje prirojenih napak v primarni sintezo žolčnih kislin zaradi oxidoreductase 3β-hidroksi-Δ5-c27-steroid pomanjkljivost ali Δ4-3-oxosteroid-5β-reduktazo pomanjkljivost pri dojenčkih, otrocih in mladostnikih v starosti enega meseca do 18 let in odrasli.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojke - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
irinotekan actavis 20 mg/ml koncentrat za raztopino za infundiranje
actavis group hf - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
irinotekan actavis 20 mg/ml koncentrat za raztopino za infundiranje
actavis group hf - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
irinotekan strides arcolab international 20 mg/ml koncentrat za raztopino za infundiranje
strides arcolab international limited - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
irinotekan strides arcolab international 20 mg/ml koncentrat za raztopino za infundiranje
strides arcolab international limited - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
metotreksat ebewe 20 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi
ebewe pharma - metotreksat - raztopina za injiciranje v napolnjeni injekcijski brizgi - metotreksat 20 mg / 1 ml - metotreksat
metotreksat ebewe 20 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi
ebewe pharma - metotreksat - raztopina za injiciranje v napolnjeni injekcijski brizgi - metotreksat 20 mg / 1 ml - metotreksat